The association of taxane resistance genes with the clinical course of ovarian carcinoma

Genomics

Volumn 102, Issue 2, 2013, Pages 96-101

  Ehrlichova, Marie ^a   Mohelnikova Duchonova, Beatrice ^a,c   Hrdy, Jiri ^b   Brynychova, Veronika ^a,b   Mrhalova, Marcela ^d   Kodet, Roman ^d   Rob, Lukas ^d   Pluta, Marek ^d   Gut, Ivan ^a   Soucek, Pavel ^a   Vaclavikova, Radka ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Clinical course; Cytokinesis; Gene expression; Ovarian carcinoma; Resistance; Taxane

Indexed keywords

CASPASE 2; CASPASE 9; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; ONCOPROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN KIF14; UNCLASSIFIED DRUG;

ABCB1 GENE; ABCC1 GENE; ADULT; ARTICLE; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CASP2 GENE; CASP9 GENE; CIT GENE; DISEASE COURSE; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; KIF14 GENE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; OVARY CARCINOMA; PRC1 GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CLINICAL COURSE; CYTOKINESIS; GENE EXPRESSION; OVARIAN CARCINOMA; RESISTANCE; TAXANE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BRIDGED COMPOUNDS; CASPASES; CELL CYCLE PROTEINS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KINESIN; MIDDLE AGED; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; OVARY; PERITONEUM; PROTEIN-SERINE-THREONINE KINASES; TAXOIDS; TREATMENT OUTCOME;

EID: 84880927652     PISSN: 08887543     EISSN: 10898646     Source Type: Journal    
DOI: 10.1016/j.ygeno.2013.03.005     Document Type: Article

References (35)

1. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs 2008, 68:771-789.
2. Global Cancer Facts & Figures Available from:. http://www.cancer.org.
3. Itamochi H., Kigawa J., Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008, 99:653-658.
4. Glotzer M. The molecular requirements for cytokinesis. Science 2005, 307:1735-1739.
5. Daire V., Poüs C. Kinesins and protein kinases: key players in the regulation of microtubule dynamics and organization. Arch. Biochem. Biophys. 2011, 510:83-92.
6. Gruneberg U., Neef R., Li X., Chan E.H., Chalamalasetty R.B., Nigg E.A., Barr F.A. KIF14 and citron kinase act together to promote efficient cytokinesis. J. Cell Biol. 2006, 172:363-372.
7. Thériault B.L., Pajovic S., Bernardini M.Q., Shaw P.A., Gallie B.L. Kinesin family member 14: an independent prognostic marker and potential therapeutic target for ovarian cancer. Int. J. Cancer 2012, 130:1844-1854.
8. Gai M., Camera P., Dema A., Bianchi F., Berto G., Scarpa E., Germena G., Di Cunto F. Citron kinase controls abscission through RhoA and anillin. Mol. Biol. Cell 2011, 22:3768-3778.
9. Ehrlichová M., Koc M., Truksa J., Naldová Z., Václavíková R., Kovár J. Cell death induced by taxanes in breast cancer cells: cytochrome C is released in resistant but not in sensitive cells. Anticancer. Res. 2005, 25:4215-4224.
10. Václavíková R., Boumendjel A., Ehrlichová M., Kovár J., Gut I. Modulation of paclitaxel transport by flavonoid derivatives in human breast cancer cells. Is there a correlation between binding affinity to NBD of P-gp and modulation of transport?. Bioorg. Med. Chem. 2006, 14:4519-4525.
11. Ho P.K., Hawkins C.J. Mammalian initiator apoptotic caspases. FEBS J. 2005, 272:5436-5453.
12. Vinothini G., Murugan R.S., Nagini S. Mitochondria-mediated apoptosis in patients with adenocarcinoma of the breast: correlation with histological grade and menopausal status. Breast 2011, 20:86-92.
13. Paroni G., Henderson C., Schneider C., Brancolini C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J. Biol. Chem. 2001, 276:21907-21915.
14. Surowiak P., Materna V., Maciejczyk A., Pudelko M., Suchocki S., Kedzia W., Nowak-Markwitz E., Dumanska M., Spaczynski M., Zabel M., Dietel M., Lage H. Decreased expression of p16 in ovarian cancers represents an unfavourable prognostic factor. Histol. Histopathol. 2008, 23:531-538.
15. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003, 10:159-165.
16. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 2000, 11:265-283.
17. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Puopolo M., Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncol. Res. 2007, 16:395-403.
18. Wei F.H., Zhao X.D., Zhang Y., He S.R., Yang L. The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer. Zhonghua Yi Xue Za Zhi 2007, 87:1187-1189. (Article in Chinese).
19. Auner V., Sehouli J., Oskay-Oezcelik G., Horvat R., Speiser P., Zeillinger R. ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol. Oncol. 2010, 117:198-201.
20. Heintz A.P., Odicino F., Maisonneuve P., Quinn M.A., Benedet J.L., Creasman W.T., Ngan H.Y., Pecorelli S., Beller U. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95(Suppl. 1):S161-S192.
21. Gershenson D.M., Sun C.C., Bodurka D., Coleman R.L., Lu K.H., Sood A.K., Deavers M., Malpica A.L., Kavanagh J.J. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol. Oncol. 2009, 114:48-52.
22. Ohishi Y., Oda Y., Uchiumi T., Kobayashi H., Hirakawa T., Miyamoto S., Kinukawa N., Nakano H., Kuwano M., Tsuneyoshi M. ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin. Cancer Res. 2002, 8:3767-3775.
23. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., Gallo D., Martinelli E., Ranelletti F.O., Ferrandina G., Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11:298-305.
24. Sakaeda T., Nakamura T., Okumura K. Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Top. Med. Chem. 2004, 4:1385-1398.
25. Matson D.R., Stukenberg P.T. Spindle poisons and cell fate: a tale of two pathways. Mol. Interv. 2011, 11:141-150.
26. Kovar J., Ehrlichova M., Smejkalova B., Zanardi I., Ojima I., Gut I. Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells. Anticancer. Res. 2009, 29:2951-2960.
27. Mhaidat N.M., Wang Y., Kiejda K.A., Zhang X.D., Hersey P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol. Cancer Ther. 2007, 6:752-761.
28. Kleinberg L., Dong H.P., Holth A., Risberg B., Trope' C.G., Nesland J.M., Flørenes V.A., Davidson B. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum. Pathol. 2009, 40:795-806.
29. Ohta T., Isobe M., Takahashi T., Saitoh-Sekiguchi M., Motoyama T., Kurachi H. The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer. Res. 2009, 29:4639-4647.
30. Materna V., Surowiak P., Markwitz E., Spaczynski M., Drag-Zalesinska M., Zabel M., Lage H. Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol. Rep. 2007, 17:505-516.
31. Soucek P., Anzenbacher P., Skoumalova I., Dvorak M. Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells. 2005, 23:1417-1422.
32. Hubackova M., Vaclavikova R., Ehrlichova M., Mrhalova, Kodet R., Kubackova K., Vrána D., Gut I., Soucek P. Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer 2012, 130:338-348.
33. Li Y.L., Feng Y., Ying H., Wei-Guo L., Xing X. Identification of suitable reference genes for gene expression studies of human serous ovarian cancer by real-time polymerase chain reaction. Anal. Biochem. 2009, 394:110-116.
34. Bustin S.A., Benes V., Garson J.A., et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009, 55:611-622.
35. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression 865 software tool (REST) for group-wise comparison and statistical analysis of relative expression results in realtime PCR. Nucleic Acids Res. 2002, 3:e36.